Atara Biotherapeutics Reports Q3 Earnings Beat with Improved EPS and Revenue
Atara Biotherapeutics (ATRA) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.15, beating estimates by $0.07, while revenue reached $1.22 million, surpassing projections by $0.69 million despite a 65.1% year-over-year decline. Management is focusing on aggressive cost-reduction initiatives implemented throughout 2025 and the first half of 2026 to drive down operating expenses. Based on these efficiencies and current liquidity, Atara expects its cash reserves and short-term investments to sustain operations into mid-2027.
Tickers: $ATRA
Topics: cash runway cost reduction earnings beat revenue decline